39.72 USD
-0.49 (-1.22%)
39.72 USD
0 (0%)
RPRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. While RPRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
- In the past year RPRX was profitable.
- In the past year RPRX had a positive cash flow from operations.
- RPRX had positive earnings in each of the past 5 years.
- RPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- RPRX's Return On Assets of 3.95% is amongst the best of the industry. RPRX outperforms 84.74% of its industry peers.
- With an excellent Return On Equity value of 11.93%, RPRX belongs to the best of the industry, outperforming 86.32% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 6.43%, RPRX belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.84%.
- The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
- The Profit Margin of RPRX (32.55%) is better than 95.26% of its industry peers.
- In the last couple of years the Profit Margin of RPRX has declined.
- Looking at the Operating Margin, with a value of 65.22%, RPRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
- RPRX's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
- The number of shares outstanding for RPRX has been reduced compared to 1 year ago.
- The number of shares outstanding for RPRX has been increased compared to 5 years ago.
- RPRX has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.70, we must say that RPRX is in the distress zone and has some risk of bankruptcy.
- RPRX has a Altman-Z score of 1.70. This is comparable to the rest of the industry: RPRX outperforms 56.84% of its industry peers.
- RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
- RPRX's Debt to FCF ratio of 9.47 is fine compared to the rest of the industry. RPRX outperforms 79.47% of its industry peers.
- RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
- RPRX's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. RPRX is outperformed by 76.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.7 |
ROIC/WACC0.75
WACC8.57%
2.3 Liquidity
- RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- RPRX has a Current ratio (3.48) which is comparable to the rest of the industry.
- RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of RPRX (3.48) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 0.24% over the past year.
- The earnings per share for RPRX have been decreasing by -18.23% on average. This is quite bad
- RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
- The Revenue has been growing slightly by 4.52% on average over the past years.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
- RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.53% yearly.
- RPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.65% yearly.
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.65%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 9.66, the valuation of RPRX can be described as very reasonable.
- Based on the Price/Earnings ratio, RPRX is valued cheaply inside the industry as 91.05% of the companies are valued more expensively.
- RPRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.54.
- Based on the Price/Forward Earnings ratio of 7.67, the valuation of RPRX can be described as very cheap.
- RPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 91.58% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.31. RPRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.66 | ||
| Fwd PE | 7.67 |
4.2 Price Multiples
- Based on the Price/Free Cash Flow ratio, RPRX is valued cheaply inside the industry as 83.68% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.27 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RPRX has a very decent profitability rating, which may justify a higher PE ratio.
- RPRX's earnings are expected to grow with 13.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y13.48%
5. Dividend
5.1 Amount
- RPRX has a Yearly Dividend Yield of 2.19%.
- Compared to an average industry Dividend Yield of 0.35, RPRX pays a better dividend. On top of this RPRX pays more dividend than 94.21% of the companies listed in the same industry.
- RPRX's Dividend Yield is comparable with the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.19% |
5.2 History
- RPRX has been paying a dividend for over 5 years, so it has already some track record.
- RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
- 49.36% of the earnings are spent on dividend by RPRX. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
39.72
-0.49 (-1.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners81.5%
Inst Owner Change0.13%
Ins Owners1.56%
Ins Owner Change7.63%
Market Cap22.93B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts84.29
Price Target46.34 (16.67%)
Short Float %7.15%
Short Ratio6.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.19% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)0.74%
PT rev (3m)4.57%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)2.06%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)4.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.2%
Revenue NY rev (1m)0.39%
Revenue NY rev (3m)1.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.66 | ||
| Fwd PE | 7.67 | ||
| P/S | 9.76 | ||
| P/FCF | 24.27 | ||
| P/OCF | 9.53 | ||
| P/B | 3.57 | ||
| P/tB | 4.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.35%
EPS(NY)5.18
Fwd EY13.04%
FCF(TTM)1.64
FCFY4.12%
OCF(TTM)4.17
OCFY10.49%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.56
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.7 |
F-Score5
WACC8.57%
ROIC/WACC0.75
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y17.31%
EPS Next 2Y12.38%
EPS Next 3Y13.48%
EPS Next 5Y10.53%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year16.23%
Revenue Next 2Y9.06%
Revenue Next 3Y8.38%
Revenue Next 5Y10.65%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.71%
EBIT Next 3Y14.53%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status for RPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.66 and the Price/Book (PB) ratio is 3.57.
Can you provide the dividend sustainability for RPRX stock?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.